MA30567B1 - Dérivés d'acide phénylacétique. - Google Patents

Dérivés d'acide phénylacétique.

Info

Publication number
MA30567B1
MA30567B1 MA31505A MA31505A MA30567B1 MA 30567 B1 MA30567 B1 MA 30567B1 MA 31505 A MA31505 A MA 31505A MA 31505 A MA31505 A MA 31505A MA 30567 B1 MA30567 B1 MA 30567B1
Authority
MA
Morocco
Prior art keywords
acid derivatives
phenylacetic acid
pharmaceutically acceptable
cox
compounds
Prior art date
Application number
MA31505A
Other languages
English (en)
Inventor
Lauren G Monovich
Benjamin Biro Mugrage
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667003&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30567(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30567B1 publication Critical patent/MA30567B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des composés de formule (I) leurs sels pharmaceutiquement acceptables; et leurs esters pharmaceutiquement acceptables; qui sont utiles pour le traitement de troubles dépendants de la COX-2.
MA31505A 2006-06-26 2008-12-24 Dérivés d'acide phénylacétique. MA30567B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80578406P 2006-06-26 2006-06-26

Publications (1)

Publication Number Publication Date
MA30567B1 true MA30567B1 (fr) 2009-07-01

Family

ID=38667003

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31505A MA30567B1 (fr) 2006-06-26 2008-12-24 Dérivés d'acide phénylacétique.

Country Status (27)

Country Link
US (3) US8362294B2 (fr)
EP (1) EP2046723B1 (fr)
JP (1) JP5258761B2 (fr)
KR (1) KR101380423B1 (fr)
CN (1) CN101479231A (fr)
AR (2) AR061623A1 (fr)
AU (1) AU2007265181B2 (fr)
BR (1) BRPI0713523A8 (fr)
CA (1) CA2655676C (fr)
CL (1) CL2007001857A1 (fr)
CR (1) CR10506A (fr)
EC (1) ECSP088988A (fr)
ES (1) ES2386989T3 (fr)
GT (1) GT200800296A (fr)
IL (1) IL195958A (fr)
MA (1) MA30567B1 (fr)
MX (1) MX2008016337A (fr)
MY (1) MY145122A (fr)
NO (1) NO20090292L (fr)
PE (1) PE20080213A1 (fr)
PL (1) PL2046723T3 (fr)
PT (1) PT2046723E (fr)
RU (1) RU2454402C2 (fr)
TN (1) TNSN08531A1 (fr)
TW (1) TW200817309A (fr)
WO (1) WO2008002853A2 (fr)
ZA (1) ZA200810562B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156809B2 (en) 1999-12-17 2007-01-02 Q-Tec Systems Llc Method and apparatus for health and disease management combining patient data monitoring with wireless internet connectivity
WO2011101321A1 (fr) 2010-02-19 2011-08-25 Bayer Cropscience Ag Benzoylcyclohexandiones substituées par 3-aminocarbonyle et leur utilisation comme herbicides
JP6250893B2 (ja) * 2015-02-13 2017-12-20 トヨタ自動車株式会社 ブローバイガス処理装置およびインテークマニホールド
CN105669732B (zh) * 2016-01-10 2017-05-31 沧州普瑞东方科技有限公司 一种合成4‑氟‑5‑异丙基‑2‑甲氧基苯硼酸的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133740C (fr) 1965-04-08
FI49600C (fi) 1967-12-20 1975-08-11 Ciba Geigy Ag Menetelmä substituoitujen fenyylietikkahappojen ja näiden suolojen val mistamiseksi.
JPS51149252A (en) 1975-06-14 1976-12-22 Ikeda Mohandou:Kk A process for preparing naphthylaminophenyl acetic acid derivatives
US4001878A (en) 1975-11-19 1977-01-04 Rca Corporation Charge transfer color imagers
JPS5268159A (en) 1975-12-03 1977-06-06 Ikeda Mohando Co Production of naphthyl aminophenyl acetic acid derivatives
JPS5283822A (en) 1976-01-01 1977-07-13 Ikeda Mohando Co Naphthylaminopheny acetic acid derivatives and salts thereof*
WO1982001366A1 (fr) 1980-10-20 1982-04-29 Kogyo Kk Zenyaku Procede de preparation de l'acide o-(2,6-dichloroanilino) phenyl acetique
JPS5770848A (en) 1980-10-20 1982-05-01 Zenyaku Kogyo Kk Preparation of o-substituted phenylacetic acid
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US6355680B1 (en) * 1996-02-20 2002-03-12 Exocell, Inc. Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
CN1156445C (zh) 1999-06-10 2004-07-07 沃尼尔·朗伯公司 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法
GB9922830D0 (en) 1999-09-27 1999-11-24 Novartis Ag Processes
US20030087942A1 (en) * 2001-08-31 2003-05-08 Washington University Method for the treatment and prevention of cachexia
PE20040844A1 (es) * 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
JP5283822B2 (ja) 2003-10-01 2013-09-04 ポリプラスチックス株式会社 ポリアセタール樹脂組成物
US8736057B2 (en) 2007-12-17 2014-05-27 Nippon Mining & Metals Co., Ltd. Substrate and manufacturing method therefor

Also Published As

Publication number Publication date
AU2007265181B2 (en) 2010-11-25
WO2008002853A2 (fr) 2008-01-03
US20140058129A1 (en) 2014-02-27
AU2007265181A1 (en) 2008-01-03
CN101479231A (zh) 2009-07-08
EP2046723A2 (fr) 2009-04-15
RU2454402C2 (ru) 2012-06-27
US20130012585A1 (en) 2013-01-10
IL195958A (en) 2016-09-29
KR20090025366A (ko) 2009-03-10
PL2046723T3 (pl) 2012-12-31
MY145122A (en) 2011-12-30
US20090209648A1 (en) 2009-08-20
AR061623A1 (es) 2008-09-10
BRPI0713523A2 (pt) 2012-02-14
JP2009541487A (ja) 2009-11-26
MX2008016337A (es) 2009-01-16
CL2007001857A1 (es) 2008-06-13
BRPI0713523A8 (pt) 2018-05-02
WO2008002853A3 (fr) 2008-02-07
RU2009102271A (ru) 2010-08-10
TW200817309A (en) 2008-04-16
GT200800296A (es) 2009-03-19
NO20090292L (no) 2009-01-26
CA2655676C (fr) 2014-07-22
CR10506A (es) 2009-02-02
ZA200810562B (en) 2009-11-25
ECSP088988A (es) 2009-01-30
IL195958A0 (en) 2009-09-22
CA2655676A1 (fr) 2008-01-03
EP2046723B1 (fr) 2012-07-18
AR108389A2 (es) 2018-08-15
JP5258761B2 (ja) 2013-08-07
KR101380423B1 (ko) 2014-04-01
PE20080213A1 (es) 2008-05-08
ES2386989T3 (es) 2012-09-10
US8586782B2 (en) 2013-11-19
TNSN08531A1 (en) 2010-04-14
PT2046723E (pt) 2012-09-20
US8362294B2 (en) 2013-01-29

Similar Documents

Publication Publication Date Title
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA28437B1 (fr) Composes et leurs procedes d'utilisation
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA31296B1 (fr) Derives d'imidazolidine carboxamide en tant qu'inhibiteurs de lipase et de phospholipase
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA31373B1 (fr) Composes amino-heterocycliques
MA29909B1 (fr) Derives de pyridazine
MA35285B1 (fr) Indazoles
MA32904B1 (fr) Composes de purine
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
TN2009000138A1 (fr) Biaryl-ether-urees
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA32598B1 (fr) Nouveaux benzamides, leur preparation et leur utilisation comme medicaments
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA30602B1 (fr) Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs